Work ability and quality of working life in atopic dermatitis patients treated with dupilumab.
atopic dermatitis
dupilumab
occupation
routine clinical care
work
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
09
04
2021
received:
05
03
2021
accepted:
12
04
2021
pubmed:
21
5
2021
medline:
4
9
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
Atopic dermatitis is associated with work productivity loss. Little is known about how patients perceive their work ability and quality of working life, and how this is affected by treatment. Our primary objective was to investigate work ability and quality of working life at baseline and during treatment in the long term. A registry-embedded prospective observational cohort study was conducted consisting of patients with atopic dermatitis starting dupilumab in routine clinical care. The instruments used were the Work Ability Index (WAI; questions 1, 2, and 3) and the Quality of Working Life Questionnaire (QWLQ). Ninety-three patients were included of whom 72 were (self-)employed (77%). From baseline to 48 weeks, the mean WAI-1 score (general work ability, range 0-10) improved from 6.8 (±2.0) to 7.9 (±1.3), WAI-2 (physical work ability, range 1-5) from 3.7 (±0.9) to 4.3 (±0.7), and WAI-3 (mental/emotional work ability, range 1-5) from 3.4 (±0.9) to 3.9 (±0.8) (p = 0.001, p = 0.005, p < 0.001, respectively). The mean QWLQ total score improved from 74.0 (±9.1) to 77.5 (±9.6) and subscale "Problems due to health situation" improved from 37.4 (±22.3) to 61.5 (±23.1) (range 0-100; p = 0.032, p < 0.001, respectively). In conclusion, patients with moderate-to-severe atopic dermatitis starting dupilumab report decreased work ability and quality of working life, mainly due to health-related problems. Significant improvement of work ability and quality of working life is observed with dupilumab treatment.
Identifiants
pubmed: 34013539
doi: 10.1111/1346-8138.15939
pmc: PMC8453967
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
dupilumab
420K487FSG
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1305-1314Subventions
Organisme : ZonMw
ID : 80-84800-98-34005
Pays : Netherlands
Informations de copyright
© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
BMC Res Notes. 2016 Apr 19;9:226
pubmed: 27094345
J Am Acad Dermatol. 2017 Aug;77(2):274-279.e3
pubmed: 28606711
JAMA Dermatol. 2017 May 1;153(5):406-412
pubmed: 28249066
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1331-1340
pubmed: 31002197
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Eur Acad Dermatol Venereol. 2018 Jan;32(1):23-38
pubmed: 28833648
Eur J Cancer Care (Engl). 2018 Nov;27(6):e12910
pubmed: 30178900
Lancet. 2020 Aug 1;396(10247):345-360
pubmed: 32738956
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
Scand J Work Environ Health. 2009 Jan;35(1):1-5
pubmed: 19277432
Br J Dermatol. 2019 Oct;181(4):761-769
pubmed: 30729499
Scand J Work Environ Health. 2009 Jul;35(4):261-81
pubmed: 19562236
Br J Dermatol. 2019 Apr;180(4):790-801
pubmed: 29761486
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
Br J Dermatol. 2020 Apr;182(4):1007-1016
pubmed: 31260080
J Occup Rehabil. 2019 Sep;29(3):540-549
pubmed: 30406343
Br J Dermatol. 1994 Sep;131(3):406-16
pubmed: 7918017
Inflamm Bowel Dis. 2021 Feb 16;27(3):352-363
pubmed: 32378704
Int J Environ Res Public Health. 2019 Sep 12;16(18):
pubmed: 31547466
BMC Cancer. 2018 Jan 10;18(1):66
pubmed: 29321006
Br J Dermatol. 2019 Sep;181(3):492-504
pubmed: 30719709
BMJ Open. 2011 Dec 03;1(2):e000190
pubmed: 22138895
Dig Dis Sci. 2021 Sep;66(9):2916-2924
pubmed: 33063191
J Cancer Surviv. 2016 Apr;10(2):394-405
pubmed: 26370284
Occup Med (Lond). 2002 Jun;52(4):177-81
pubmed: 12091582
Hautarzt. 2018 Oct;69(10):815-824
pubmed: 30191254
BMC Health Serv Res. 2016 Jun 02;16:194
pubmed: 27250336
Acta Derm Venereol. 2019 Jul 1;99(9):762-768
pubmed: 31073619
Br J Dermatol. 2020 Nov;183(5):891-898
pubmed: 32107772